Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$11.19
▼ $0.17 (-1.5%)
Market data updated: 09/20 08:41 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$221.87M
Day Range
$11.10 - $11.36
52-Week Range
$9.69 - $22.55
Beta
—
Next Earnings
03.11.2026
Support
$9.69
Resistance
$12.19
KROS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-30.2% (1Y)
Strengths: 20/26 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $36.98 vs. price $11.19 (+230.4%)
Fair Value
Biggest negative driver
Daily volatility (ATR)
ATR: 4.3% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
67
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
74
Quality
58
Value
67
Momentum
72
Risk
40
Sentiment
56
Fundamental
74
Institutional
29
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Keros Therapeutics** has centered on its financial and strategic shifts, including a **$5 million share buyback** and a **$20 million milestone payment from Takeda**, which analysts speculate could unlock broader commercial potential. However, the company faced **declining revenues (falling to zero in Q2 2026)** and **missed earnings expectations**, raising concerns about near-term profitability despite a strong clinical-stage pipeline. Analysts remain cautiously optimistic, though price targets were recently adjusted downward.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Keros Therapeutics, Inc.. News trend score: 56. Reason: 6 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
13
🎯 Conviction (vs. Emotion)
52
Psychology
60
Fundamentals
74
Technical
72
Valuation
67
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+5%
Market Narrative
35
Fundamental Reality
52
Narrative Gap
-17
🧠 StockIQ Psychologist
KROS’s dominant **herding** behavior suggests traders are aligning with peers after relative underperformance, despite modest FOMO signals from momentum and volume. The narrative gap (-18) hints at a disconnect where market sentiment (34) lags fundamentals (52), possibly reinforcing herd-driven decisions. Overconfidence and loss aversion remain negligible, while anchoring near resistance may subtly influence positioning. The key question is whether the underperformance persists or if traders will pivot if peers rally.
Updated: 09/09/2026, 06:35 AM
What could change this?
👥 What the crowd believes
"$20M Takeda milestone adds cash but revenue visibility remains weak"
"Q2 EPS $(1.45) misses $(1.34) estimate by 8.21%"
"Revenue visibility stays weak, pipeline in focus"
"$5 million share repurchase authorization"
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Jesse Livermore — 28/100
🗣️ Why do they disagree?
This stock’s stark divide in methodology verdicts reflects a clash between growth-focused value investors and more cautious or cyclical-minded strategists. The highest scores—from Bagehot, Graham (Defensive), Lynch, and Fisher—highlight its perceived strength in liquidity, undervaluation, and quality, suggesting a consensus among traditional value and growth-oriented investors that the stock offers compelling fundamentals. Conversely, the lower scores—particularly from Nelson, Loeb, and Livermore—stem from concerns about speculative overvaluation, cyclical positioning, or lack of clear trend momentum, painting a picture of risk aversion or skepticism about timing. Even the middle-ground approaches, like Marks’ risk assessment or the efficient-market skeptics, reveal a tension between opportunity and uncertainty, with some seeing reasonable value while others dismiss it as unconvincing or overbought.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 95
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 95
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 94
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 93
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 78
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 77
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 68
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 55
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 53
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 52
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 45
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 41
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 28
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
27.7%
Net Margin
35.7%
EBITDA Margin
27.7%
ROE
28.7%
ROA
25.7%
ROIC
—
EPS
$2.34
Cash
$287.42M
Total Debt
—
Current Ratio
15.45
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$11.19
Estimated Fair Value (DCF)
$36.98
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+230.4%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
-5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -5.0% | $100.66M | $92.35M |
| 2 | -3.1% | $97.51M | $82.07M |
| 3 | -1.2% | $96.29M | $74.36M |
| 4 | 0.6% | $96.89M | $68.64M |
| 5 | 2.5% | $99.32M | $64.55M |
Base FCF (last actual year)
$105.95M
Terminal Value
$1.57B
Present Value of Terminal Value
$1.02B
Enterprise Value
$1.40B
Net Debt
$0
Equity Value
$1.40B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$8.01
Tangible Book Value per Share (Tangible NAV)
$8.01
Sentiment based on basic keywords (not AI) — 6 positive, 9 neutral, 5 negative out of the last 20 articles.
Benzinga · 10.9.2026
MT Newswires · 8.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Benzinga · 8.9.2026
Yahoo · 2.9.2026
Zacks · 2.9.2026
Zacks · 24.8.2026
Zacks · 24.8.2026
Insider Monkey · 14.8.2026
Zacks · 4.8.2026
Benzinga · 4.8.2026
GlobeNewswire · 3.8.2026
Yahoo · 3.8.2026
Benzinga · 3.8.2026
GlobeNewswire · 30.7.2026
Yahoo · 30.7.2026
Benzinga · 30.7.2026
Zacks · 28.7.2026
Zacks · 26.6.2026
Keros Therapeutics, Inc. (KROS) currently has a StockIQ AI score of 67/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
KROS currently scores 67/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, KROS's estimated fair value is $36.98, which is 230.4% above the current price of $11.19. This is one valuation model among several signals in the fair-value category, not a price target.
KROS's technical score is 72/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $36.98 vs. price $11.19 (+230.4%); Earnings per share (EPS) growth: 146.0%; Free cash flow growth: 165.1%.
Based on the real signals StockIQ computed: ATR: 4.3% of price; Calmar: -0.37 (3y annualized return -31.7% / max drawdown 86.5%); Price is below the 200-day average.
StockIQ has no recorded dividend payment history for KROS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 5 purchases and 12 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Newton Charles W. | Open Market Sale | 18.8.2026 | 551 | -551 | $10.30 |
| Tanini Annita | Open Market Sale | 18.8.2026 | 1,224 | -1,224 | $10.29 |
| Lerner Lorena Raquel | Open Market Sale | 18.8.2026 | 3,568 | -3,568 | $10.29 |
| Cho Esther | Open Market Sale | 18.8.2026 | 4,485 | -4,485 | $10.29 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 17.8.2026 | 1,000 | +1,000 | $10.27 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 15.7.2026 | 1,000 | +1,000 | $10.61 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 15.7.2026 | 18,592 | +1,000 | $10.61 |
| Prener Anne | Grant/Award from Employer | 1.7.2026 | 14,870 | +14,870 | — |
| Prener Anne | Grant/Award from Employer | 1.7.2026 | 13,786 | +13,786 | — |
| Prener Anne | Grant/Award from Employer | 1.7.2026 | 13,786 | +13,786 | — |
| Prener Anne | Grant/Award from Employer | 1.7.2026 | 14,870 | +14,870 | — |
| BIENAIME JEAN JACQUES | Open Market Purchase | 15.6.2026 | 1,000 | +1,000 | $10.19 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 15.6.2026 | 17,592 | +1,000 | $10.19 |
| Newton Charles W. | Open Market Sale | 11.6.2026 | 550 | -550 | $10.04 |
| Newton Charles W. | Open Market Sale | 11.6.2026 | 12,665 | -550 | $10.04 |
| Seth Alpna | Open Market Sale | 4.6.2026 | 2,625 | -2,625 | $10.72 |
| Knowles Julius | Open Market Sale | 4.6.2026 | 2,625 | -2,625 | $10.73 |
| Farzan Nima | Open Market Sale | 4.6.2026 | 2,625 | -2,625 | $10.73 |
| Seth Alpna | Open Market Sale | 4.6.2026 | 9,767 | -2,625 | $10.72 |
| Farzan Nima | Open Market Sale | 4.6.2026 | 9,767 | -2,625 | $10.73 |
| Knowles Julius | Open Market Sale | 4.6.2026 | 10,958 | -2,625 | $10.73 |
| GRAY MARY ANN | Grant/Award from Employer | 3.6.2026 | 7,433 | +7,433 | — |
| GRAY MARY ANN | Grant/Award from Employer | 3.6.2026 | 7,142 | +7,142 | — |
| Seth Alpna | Grant/Award from Employer | 3.6.2026 | 7,433 | +7,433 | — |
| Farzan Nima | Grant/Award from Employer | 3.6.2026 | 7,142 | +7,142 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,165,086 shares short as of 2026-08-31 · vs. 985,590 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
40.2% of trading volume this week was short selling, vs. 47.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology